Plant Name: Psychotria klugii
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CXCR1; NPSR1; | |
| ADRA2C; ADRA2A; DRD4; | |
| RBBP9; RECQL; PLA2G1B; PIK3R1; MTOR; GLO1; MPO; AKR1B1; HSD17B2; ALOX12; ALOX15; NOX4; HSD17B10; PYGL; POLB; | |
| NEK6; DAPK1; AKT1; ALK; CAMK2B; AXL; MET; FLT3; PKN1; CDK1; PIM1; IGF1R; NUAK1; NEK2; KDR; GSK3B; SRC; PTK2; AURKB; CSNK2A1; | |
| CA2; CA9; CA12; CA5A; CA3; CA14; CA7; CA4; CA6; CA1; | |
| KDM4E; | |
| MAOA; ALOX5; XDH; | |
| BACE1; | |
| MMP13; MMP9; MMP3; MMP2; | |
| HIF1A; TP53; NFKB1; STAT6; | |
| SLC2A1; | |
| ABCG2; ABCC1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | RBBP9 | Putative hydrolase RBBP9 | O75884 | CHEMBL1075121 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| SLC superfamily of solute carriers | SLC2A1 | Glucose transporter | P11166 | CHEMBL2535 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005524; ATP binding | 6.641E-12 | 3.998E-09 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MET, MTOR, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.082E-10 | 7.952E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.005E-10 | 1.128E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.953E-10 | 1.435E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, XDH |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.077E-09 | 3.169E-07 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MTOR, NEK2, NEK6, NUAK1, PIM1, PKN1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.110E-09 | 3.223E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, MPO, NOX4, SRC |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 1.045E-08 | 2.321E-06 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MTOR, NEK6, PKN1, SRC |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.587E-08 | 3.261E-06 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MTOR, PKN1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.663E-08 | 6.703E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 9.845E-08 | 1.553E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 1.598E-07 | 2.368E-05 | ADRA2A, ADRA2C, AKT1, MTOR, SRC |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.981E-07 | 2.838E-05 | CYP1A2, CYP2C8, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.490E-07 | 3.388E-05 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, GLO1, MMP13, MMP2, MMP3, MMP9, TP53 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.873E-07 | 3.838E-05 | ABCG2, ADRA2A, ADRA2C, AKT1, ALK, CAMK2B, CSNK2A1, DAPK1, DRD4, FLT3, IGF1R, KDR, MET, MMP9, MTOR, NFKB1, PYGL, SLC2A1, STAT6, TP53, XDH |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 4.939E-07 | 6.253E-05 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 9.852E-07 | 1.179E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.012E-06 | 1.198E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.562E-06 | 1.762E-04 | AXL, MET, MTOR, NOX4, PIK3R1, PTK2, SRC |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 2.744E-06 | 2.886E-04 | ADRA2A, ADRA2C, DRD4 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.758E-06 | 2.887E-04 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 3.161E-06 | 3.231E-04 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 3.423E-06 | 3.466E-04 | ADRA2A, ADRA2C, AKT1, AXL, PIK3R1, SRC |
| MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 5.144E-06 | 5.000E-04 | AKT1, MET, NEK2, PIK3R1, STAT6, TP53 |
| BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 5.848E-06 | 5.635E-04 | ABCC1, ABCG2, SLC2A1 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 7.201E-06 | 6.818E-04 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 7.709E-06 | 7.112E-04 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 9.400E-06 | 8.388E-04 | AKR1B1, AKT1, MMP2, MMP9, MTOR |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.008E-05 | 8.957E-04 | ADRA2A, AURKB, CA2, CA7, HIF1A, KDR, NEK2, NPSR1, PLA2G1B, SRC |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.066E-05 | 9.263E-04 | CYP1A2, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.066E-05 | 9.263E-04 | CYP1A2, CYP2C8, CYP3A4 |
| MF | GO:0005488; binding | GO:0008134; transcription factor binding | 1.097E-05 | 9.444E-04 | FLT3, GSK3B, HIF1A, MTOR, NEK6, NFKB1, PIK3R1, PIM1, PKN1, SRC, TP53 |
| BP | GO:0051179; localization | GO:0051050; positive regulation of transport | 1.103E-05 | 9.460E-04 | ADRA2A, AKT1, AXL, CA2, CDK1, CYP19A1, DRD4, GSK3B, HIF1A, NPSR1, PIK3R1, PLA2G1B, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.370E-05 | 1.126E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.370E-05 | 1.126E-03 | ALOX12, ALOX15 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.721E-05 | 1.388E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 2.053E-05 | 1.614E-03 | ALOX15, GSK3B, MET, MMP3, MTOR, SRC, TP53 |
| BP | GO:0051179; localization | GO:0060341; regulation of cellular localization | 2.069E-05 | 1.621E-03 | ADRA2A, AKT1, CDK1, CSNK2A1, DRD4, GSK3B, HIF1A, MTOR, NPSR1, PIK3R1, PLA2G1B, SRC, TP53 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.113E-05 | 1.649E-03 | AURKB, CA2, CA7, HIF1A, NEK2, NPSR1, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 2.147E-05 | 1.670E-03 | AKT1, MTOR, NOX4, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.686E-05 | 2.017E-03 | ALOX12, ALOX15, ALOX5 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.804E-05 | 2.098E-03 | IGF1R, KDR, PTK2, SRC |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 2.824E-05 | 2.099E-03 | ADRA2A, AKT1, HIF1A, NOX4, PIK3R1, PYGL |
| BP | GO:0000003; reproduction | GO:0022414; reproductive process | 3.183E-05 | 2.318E-03 | ADRA2C, AKR1B1, AKT1, AXL, CDK1, CYP19A1, CYP1A1, HIF1A, HSD17B2, MMP2, MMP9, MTOR, NEK2, PTK2, SLC2A1, SRC |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 3.252E-05 | 2.361E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 3.572E-05 | 2.560E-03 | AKR1B1, ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP3A4, MPO, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.101E-05 | 2.862E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.101E-05 | 2.862E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 4.101E-05 | 2.862E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 4.101E-05 | 2.862E-03 | ADRA2A, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 4.101E-05 | 2.862E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 4.316E-05 | 2.955E-03 | AKT1, HIF1A, MTOR, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0050731; positive regulation of peptidyl-tyrosine phosphorylation | 4.533E-05 | 3.065E-03 | ADRA2A, ADRA2C, FLT3, MTOR, SRC, TP53 |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 5.170E-05 | 3.443E-03 | AKT1, ALOX15, AXL, DAPK1, FLT3, GSK3B, HIF1A, NFKB1 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 5.171E-05 | 3.443E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 5.441E-05 | 3.590E-03 | ADRA2C, AKT1, ALOX12, AXL, CA2, CAMK2B, CDK1, CYP1B1, HIF1A, KDR, MTOR, NFKB1, PIM1, SRC, STAT6 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 6.294E-05 | 4.103E-03 | CYP1A1, POLB, TP53 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 6.782E-05 | 4.369E-03 | ABCC1, ADRA2A, CA2, CA4, CA9, SLC2A1 |
| BP | GO:0050896; response to stimulus | GO:0071214; cellular response to abiotic stimulus | 7.515E-05 | 4.716E-03 | AKT1, AURKB, NFKB1, NOX4, PIK3R1, SLC2A1, TP53 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 8.181E-05 | 5.033E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 8.181E-05 | 5.033E-03 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.181E-05 | 5.033E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 8.336E-05 | 5.113E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:2000573; positive regulation of DNA biosynthetic process | 9.521E-05 | 5.759E-03 | AURKB, NEK2, NOX4, SRC |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 1.012E-04 | 6.019E-03 | MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0009987; cellular process | GO:0007569; cell aging | 1.012E-04 | 6.019E-03 | CDK1, MTOR, NOX4, TP53 |
| BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 1.088E-04 | 6.402E-03 | ADRA2A, AKT1, CDK1, DAPK1, GSK3B, HIF1A, KDR, PTK2 |
| BP | GO:0008152; metabolic process | GO:0045862; positive regulation of proteolysis | 1.088E-04 | 6.402E-03 | ADRA2A, AKT1, CDK1, DAPK1, GSK3B, PTK2, SRC, XDH |
| BP | GO:0051179; localization | GO:0046903; secretion | 1.150E-04 | 6.716E-03 | ALOX5, AXL, CA2, CA9, CXCR1, DRD4, HIF1A, MMP9, MPO, NFKB1, PLA2G1B, PYGL, XDH |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 1.207E-04 | 6.975E-03 | AKT1, HIF1A, NFKB1, SRC |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.214E-04 | 6.975E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.255E-04 | 7.189E-03 | CA2, CA7, KDR, NPSR1, PLA2G1B, SRC |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.360E-04 | 7.566E-03 | ALOX12, ALOX15 |
| BP | Unclassified; | GO:0051534; negative regulation of NFAT protein import into nucleus | 1.360E-04 | 7.566E-03 | GSK3B, MTOR |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 1.351E-04 | 7.566E-03 | GSK3B, HIF1A, NUAK1, TP53 |
| MF | GO:0005488; binding | GO:0051380; norepinephrine binding | 1.360E-04 | 7.566E-03 | ADRA2A, DRD4 |
| BP | GO:0008152; metabolic process | GO:0016572; histone phosphorylation | 1.521E-04 | 8.201E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 1.644E-04 | 8.840E-03 | ADRA2C, AKT1, ALOX12, AXL, CA2, CAMK2B, CDK1, CYP1B1, GSK3B, HIF1A, KDR, MTOR, PIK3R1, PIM1, PTK2, SRC, STAT6, XDH |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.693E-04 | 9.077E-03 | AXL, IGF1R, PIK3R1 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.859E-04 | 9.817E-03 | AXL, CDK1, CSNK2A1, FLT3 |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 1.876E-04 | 9.817E-03 | FLT3, PTK2, SRC |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.983E-22 | 8.691E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.059E-16 | 2.199E-12 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.188E-15 | 9.782E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.631E-21 | 6.246E-19 | CA12; CA1; CA3; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.458E-13 | 2.974E-11 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; MMP9; PTK2; MTOR; IGF1R; KDR; AKT1; TP53; MET |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 9.287E-12 | 5.325E-10 | GSK3B; FLT3; DAPK1; MMP2; SLC2A1; PIK3R1; HIF1A; MMP9; NFKB1; MTOR; PTK2; IGF1R; AKT1; MET; TP53 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.041E-10 | 4.475E-09 | FLT3; SLC2A1; AKT1; PIK3R1; TP53; MET; HIF1A; MTOR |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.424E-09 | 1.178E-07 | CAMK2B; SLC2A1; AKT1; PIK3R1; HIF1A; NFKB1; MTOR; IGF1R |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.009E-08 | 2.893E-07 | GSK3B; SRC; SLC2A1; AKT1; PIK3R1; TP53; HIF1A; MTOR |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.602E-08 | 5.632E-07 | GSK3B; KDR; AKT1; PIK3R1; PKN1; TP53; MET; PTK2; NFKB1; MTOR; IGF1R |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.468E-08 | 5.163E-07 | ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 3.167E-08 | 5.448E-07 | GSK3B; AKT1; PIK3R1; TP53; NFKB1; MTOR; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.701E-08 | 5.163E-07 | CAMK2B; GSK3B; SRC; AKT1; PIK3R1; MTOR; PTK2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.658E-08 | 4.073E-07 | FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 5.525E-08 | 7.549E-07 | FLT3; PIM1; AKT1; PIK3R1; NFKB1; MTOR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.229E-07 | 1.391E-06 | CAMK2B; AKT1; PIK3R1; TP53; MTOR; IGF1R |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.294E-07 | 1.391E-06 | GSK3B; SLC2A1; AKT1; PIK3R1; PYGL; NFKB1; MTOR |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 6.486E-07 | 6.198E-06 | GSK3B; SRC; KDR; AKT1; PIK3R1; MET; PTK2; IGF1R |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.145E-08 | 7.549E-07 | CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 9.475E-07 | 8.578E-06 | SRC; AKT1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.116E-06 | 9.601E-06 | AKT1; PIK3R1; TP53; NFKB1; MTOR; IGF1R |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.557E-07 | 3.599E-06 | DAPK1; SRC; MMP2; MMP9; TP53 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.671E-06 | 2.187E-05 | SRC; KDR; AKT1; PIK3R1; PTK2 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 4.925E-06 | 3.388E-05 | GSK3B; CXCR1; SRC; AKT1; PIK3R1; NFKB1; PTK2 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.830E-08 | 7.549E-07 | CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 4.653E-06 | 3.335E-05 | CAMK2B; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 8.168E-06 | 5.017E-05 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.897E-06 | 2.265E-05 | CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 3.956E-06 | 2.959E-05 | SLC2A1; AKT1; PIK3R1; MET; HIF1A |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.130E-05 | 6.410E-05 | ABCC1; PIM1; CYP1B1; TP53; MMP9; MET; NFKB1; MTOR |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 5.684E-06 | 3.760E-05 | AKT1; PIK3R1; TP53; MET; IGF1R |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 9.568E-06 | 5.675E-05 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 6.091E-06 | 3.880E-05 | GSK3B; SRC; AKT1; PIK3R1; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.742E-05 | 8.811E-05 | PLA2G1B; KDR; AKT1; PIK3R1; MET; NFKB1; IGF1R |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.847E-05 | 1.380E-04 | PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; CYP3A4; CYP19A1; HSD17B10; CYP2C8; ALOX5; HSD17B2; CYP1A2; CYP1A1; XDH |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.181E-05 | 1.479E-04 | MMP2; PIM1; AKT1; PIK3R1; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 3.951E-05 | 1.743E-04 | POLB; GSK3B; SLC2A1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.458E-05 | 7.600E-05 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.888E-05 | 1.380E-04 | SRC; MMP2; AKT1; PIK3R1; MMP9 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.155E-05 | 6.410E-05 | CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.793E-05 | 2.061E-04 | MMP3; AKT1; PIK3R1; MMP9; NFKB1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.225E-05 | 2.140E-04 | CYP2C8; MAOA; ALOX5; ALOX15; ALOX12 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 9.593E-05 | 3.367E-04 | POLB; SRC; CDK1; PIK3R1; TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 7.258E-05 | 2.811E-04 | ABCC1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.124E-04 | 3.647E-04 | SRC; KDR; AKT1; PIK3R1; MET; IGF1R |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.022E-04 | 3.517E-04 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.181E-04 | 3.699E-04 | GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 3.668E-05 | 1.660E-04 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 4.922E-05 | 2.065E-04 | ALK; AKT1; PIK3R1; TP53 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 6.464E-05 | 2.586E-04 | AKT1; PIK3R1; HIF1A; MTOR |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 8.332E-05 | 3.115E-04 | AKT1; PIK3R1; MTOR; IGF1R |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 2.638E-04 | 7.089E-04 | PIM1; AKT1; STAT6; PIK3R1; MTOR |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.453E-04 | 4.074E-04 | GSK3B; AKT1; PIK3R1; PYGL; MTOR |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 7.355E-05 | 2.811E-04 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 9.400E-05 | 3.367E-04 | AKT1; PIK3R1; TP53; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.279E-05 | 6.875E-05 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.854E-05 | 3.240E-04 | CYP2C8; CYP1A2; CYP1A1; CYP3A4 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 4.320E-04 | 1.126E-03 | CAMK2B; SRC; ALOX12; PIK3R1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.056E-04 | 3.563E-04 | CXCR1; SRC; MET; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 4.320E-04 | 1.126E-03 | CDK1; AKT1; PIK3R1; IGF1R |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.637E-03 | 3.857E-03 | AKT1; PIK3R1; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.393E-04 | 3.993E-04 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.844E-04 | 1.225E-03 | AKT1; PIK3R1; HIF1A; MTOR |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 2.420E-03 | 5.336E-03 | CXCR1; SRC; KDR; MET; IGF1R |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.118E-04 | 3.647E-04 | CYP2C8; MAOA; CYP1A2; CYP3A4 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.393E-04 | 3.993E-04 | AKT1; PIK3R1; TP53; NFKB1 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 4.844E-04 | 1.225E-03 | CAMK2B; SLC2A1; AKT1; PYGL |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.724E-03 | 3.954E-03 | CAMK2B; GSK3B; CSNK2A1; TP53 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.183E-04 | 3.699E-04 | SLC2A1; AKT1; NFKB1; MTOR |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 2.157E-03 | 4.819E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 5.411E-04 | 1.349E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.815E-03 | 4.107E-03 | CXCR1; AKT1; PIK3R1; MTOR |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.724E-03 | 3.954E-03 | GSK3B; AKT1; PIK3R1; IGF1R |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 8.695E-04 | 2.106E-03 | ALOX5; AKT1; PIK3R1; NFKB1 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.046E-03 | 2.498E-03 | AKT1; PIK3R1; MTOR; IGF1R |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 8.695E-04 | 2.106E-03 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 3.669E-03 | 7.790E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 3.103E-03 | 6.672E-03 | AKT1; PIK3R1; ADRA2C; ADRA2A |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.250E-04 | 3.830E-04 | CA2; SLC2A1; CYP3A4; ABCG2 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 3.898E-03 | 8.175E-03 | CAMK2B; SRC; AKT1; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 4.469E-03 | 9.151E-03 | CSNK2A1; CDK1; TP53; NFKB1 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.801E-04 | 4.917E-04 | SRC; PIK3R1; MET; PTK2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.776E-03 | 1.155E-02 | CAMK2B; AKT1; PIK3R1; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.393E-04 | 3.993E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.469E-04 | 4.074E-04 | CSNK2A1; SRC; MET; IGF1R |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 9.728E-03 | 1.859E-02 | SRC; AKT1; PIK3R1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 7.516E-03 | 1.453E-02 | CAMK2B; AKT1; PIK3R1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 9.946E-03 | 1.880E-02 | CAMK2B; CDK1; IGF1R |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.534E-02 | 2.587E-02 | CXCR1; FLT3; KDR; MET |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 6.621E-03 | 1.294E-02 | AKT1; PIK3R1; NFKB1 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 5.636E-03 | 1.140E-02 | PIK3R1; NFKB1; PTK2 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 6.282E-03 | 1.242E-02 | AKT1; PIK3R1; NFKB1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 4.333E-03 | 8.978E-03 | CAMK2B; SRC; MMP2 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.017E-02 | 1.901E-02 | GSK3B; CDK1; TP53 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.085E-02 | 2.006E-02 | GSK3B; MET; PTK2 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.203E-02 | 2.134E-02 | AKT1; PIK3R1; NFKB1 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.228E-02 | 2.155E-02 | AKT1; PIK3R1; IGF1R |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.633E-02 | 2.726E-02 | CAMK2B; AKT1; PIK3R1 |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 1.382E-02 | 2.354E-02 | CSNK2A1; SRC; AKT1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.939E-02 | 3.147E-02 | CAMK2B; SRC; PIK3R1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.276E-02 | 3.625E-02 | BACE1; GSK3B; HSD17B10 |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 2.922E-02 | 4.448E-02 | CAMK2B; CA2 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 2.499E-02 | 3.872E-02 | AKT1; PIK3R1 |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 2.431E-02 | 3.801E-02 | CAMK2B; MAOA |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 2.567E-02 | 3.943E-02 | CDK1; TP53 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 2.297E-02 | 3.625E-02 | SRC; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 2.297E-02 | 3.625E-02 | STAT6; NFKB1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.736E-02 | 2.844E-02 | AKT1; PIK3R1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.678E-02 | 2.776E-02 | GSK3B; TP53 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.348E-02 | 2.318E-02 | MAOA; NFKB1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.296E-02 | 2.251E-02 | PIK3R1; MTOR |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 1.145E-02 | 2.073E-02 | AKT1; PIK3R1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.194E-02 | 2.134E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.097E-02 | 2.007E-02 | ABCC1; ABCG2 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.079E-03 | 6.672E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.269E-04 | 3.830E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; MMP3; PLA2G1B; ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; HIF1A; CA9; MTOR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP13; MPO; MTOR; PLA2G1B; ALOX5 |
| C00-D49: Neoplasms | Cancer | C00-C96 | FLT3; FLT3; AKT1; HIF1A; TP53; MET; CA9; CDK1; MMP9; NFKB1; MTOR; PIM1; MMP2; SRC; KDR; GSK3B; PTK2; CA1; IGF1R; CSNK2A1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; CYP19A1; CA9; CDK1; KDR; KDR; KDR; IGF1R |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; ALOX5 |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; PTK2 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; AKT1 |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR; IGF1R |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR |
| A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; MTOR |
| C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; TP53; TP53; AURKB |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; ABCC1; ABCC1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; MAOA; GSK3B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| NA: NA | Coronary artery restenosis | NA | MTOR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; TP53; MMP9; KDR; IGF1R |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; SRC; AURKB |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; KDR; IGF1R |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; CYP3A4; MAOA |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; AKT1; MTOR; MMP2; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ADRA2C; CA1; CA1 |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MMP13; CDK1; ADRA2C; MTOR; ADRA2A; IGF1R |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | AXL; MET; MTOR; KDR; IGF1R; IGF1R |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; MTOR |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
| C00-D49: Neoplasms | Multiple myeloma | C90 | MTOR; MTOR; SRC; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; KDR; KDR |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP13; MMP3; MMP2; ALOX5 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; MAOA |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; PLA2G1B; ALOX5; ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; MTOR; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | Solid tumors | NA | MTOR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; AKT1; HIF1A; TP53; MET; CA9; MMP9; MTOR; MMP2; SRC; KDR; KDR; KDR; PTK2; IGF1R; AURKB |